文献速递新发突发、热带与寄生虫病

候选血期疟疾疫苗P27A在暴露与非暴露志愿者中快速进入现场阶段的1期试验中诱导强烈体液免疫应答

The Candidate Blood-stage Malaria Vaccine P27A Induces a Robust Humoral Response in a Fast Track to the Field Phase 1 Trial in Exposed and Nonexposed Volunteers.
PubMed 文献 · Clin Infect Dis · 2019-01-01

在瑞士和坦桑尼亚开展随机、抗原与佐剂剂量探索的多中心1a/1b期试验,P27A抗原(10或50 μg)联合Alhydrogel或GLA-SE(2.5或5 μg)或对照狂犬病疫苗于第0、28、56天肌内接种16名疟疾未暴露欧洲人和40名疟疾暴露非洲人。多数不良事件轻至中度且48小时内完全缓解,无严重不良事件;P27A诱导明显特异性抗体应答,联合GLA-SE免疫原性尤为强烈;暴露的坦桑尼亚受试者不良事件发生率和抗体应答显著低于未暴露的欧洲受试者。

要点

  • P27A联合GLA-SE诱导强烈特异性抗体应答,能识别感染红细胞中的TEX1并抑制疟原虫生长。
  • 多数不良事件轻至中度、48小时内完全缓解,无严重不良事件。
  • 暴露的坦桑尼亚受试者不良事件发生率和抗体应答显著低于未暴露的欧洲受试者。

核心结论

  • 候选疫苗P27A是安全的,与GLA-SE联合时诱导尤为强烈的免疫原性应答。
  • 作者认为该制剂应考虑用于未来的效力试验。

研究设计与样本

  • 研究为交错、快速进入现场、随机、抗原与佐剂剂量探索的多中心1a/1b期试验,在瑞士和坦桑尼亚开展。
  • P27A抗原(10或50 μg)联合Alhydrogel或GLA-SE(2.5或5 μg),或对照狂犬病疫苗(Verorab),于第0、28、56天肌内接种16名疟疾未暴露者和40名疟疾暴露者。
  • 每次注射后及34周随访期间评估局部与全身不良事件以及体液和细胞免疫应答。

主要发现

  • 多数不良事件轻至中度,48小时内完全缓解。
  • 以明矾为佐剂的制剂全身不良事件较GLA-SE更频繁,而GLA-SE后局部不良事件更频繁。
  • 未发生严重不良事件。
  • 在混合Th1/Th2细胞免疫支持下,P27A诱导明显的特异性抗体应答,能识别感染红细胞中的TEX1并通过抗体依赖性细胞抑制机制抑制疟原虫生长。
  • 暴露的坦桑尼亚受试者不良事件发生率和抗体应答显著低于未暴露的欧洲受试者。

临床怎么用

  • 作者认为P27A联合GLA-SE的制剂应考虑用于未来的效力试验。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: P27A is an unstructured 104mer synthetic peptide from Plasmodium falciparum trophozoite exported protein 1 (TEX1), the target of human antibodies inhibiting parasite growth. The present project aimed at evaluating the safety and immunogenicity of P27A peptide vaccine in malaria-nonexposed European and malaria-exposed African adults. METHODS: This study was designed as a staggered, fast-track, randomized, antigen and adjuvant dose-finding, multicenter phase 1a/1b trial, conducted in Switzerland and Tanzania. P27A antigen (10 or 50 μg), adjuvanted with Alhydrogel or glucopyranosil lipid adjuvant stable emulsion (GLA-SE; 2.5 or 5 μg), or control rabies vaccine (Verorab) were administered intramuscularly to 16 malaria-nonexposed and 40 malaria-exposed subjects on days 0, 28, and 56. Local and systemic adverse events (AEs) as well as humoral and cellular immune responses were assessed after each injection and during the 34-week follow-up. RESULTS: Most AEs were mild to moderate and resolved completely within 48 hours. Systemic AEs were more frequent in the formulation with alum as compared to GLA-SE, whereas local AEs were more frequent after GLA-SE. No serious AEs occurred. Supported by a mixed Th1/Th2 cell-mediated immunity, P27A induced a marked specific antibody response able to recognize TEX1 in infected erythrocytes and to inhibit parasite growth through an antibody-dependent cellular inhibition mechanism. Incidence of AEs and antibody responses were significantly lower in malaria-exposed Tanzanian subjects than in nonexposed European subjects. CONCLUSIONS: The candidate vaccine P27A was safe and induced a particularly robust immunogenic response in combination with GLA-SE. This formulation should be considered for future efficacy trials. CLINICAL TRIALS REGISTRATION: NCT01949909, PACTR201310000683408.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Steiner-Monard V, Kamaka K, Karoui O, et al. The Candidate Blood-stage Malaria Vaccine P27A Induces a Robust Humoral Response in a Fast Track to the Field Phase 1 Trial in Exposed and Nonexposed Volunteers. Clin Infect Dis. 2019. PMID: 29945169. doi:10.1093/cid/ciy514

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。